Adial Pharmaceuticals Inc.

Visit Website


1001 Research Park Blvd., Suite 100
Charlottesville, VA 22911

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of a therapeutic agent for the treatment of alcohol use disorder (AUD).  Adial plans to commence a Phase 3 clinical trial using it’s lead investigational new drug product, AD04 for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using a proprietary companion diagnostic genetic test.  AD04 is also believed to have the potential to treat other addictive disorders such as opioid use disorder, gambling, and obesity.